SHARE

Latest Pharmaceutical and Healthcare disease pipeline guide Obesity Pipeline – Pipeline Review, H1 2018, provides an overview of the Obesity Pipeline pipeline landscape.

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Obesity Pipeline – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Obesity Pipeline , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Obesity Pipeline guide also reviews of key players involved in therapeutic development for Obesity Pipeline and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are:- 1, 5, 18, 28, 1, 120, 32 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 53 and 10 molecules, respectively.

Obesity Pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Companies Mentioned in Obesity Pipeline are: Abeome Corp, Adocia SAS, Aegis Therapeutics LLC, Amgen Inc, Antag Therapeutics ApS, Aoxing Pharmaceutical Company Inc, Arrowhead Pharmaceuticals Inc, AstraZeneca Plc, Athersys Inc, Auris Medical Holding AG, Bial – Portela & Ca SA, Biophytis SA, BioRestorative Therapies Inc, Biozeus, Boehringer Ingelheim GmbH, Braasch Biotech LLC, C3J Therapeutics Inc, Callitas Therapeutics Inc, Carmot Therapeutics Inc, Celon Pharma SA, Chong Kun Dang Pharmaceutical Corp, CohBar Inc, CoMentis Inc, Corcept Therapeutics Inc, Daiichi Sankyo Co Ltd, DiscoveryBiomed Inc, Eisai Co Ltd, Eli Lilly and Co, Eternygen GmbH, Evotec AG, FibroGen Inc, Genmedica Therapeutics SL, Gila Therapeutics Inc, Gilead Sciences Inc, GlaxoSmithKline Plc, Glucox Biotech AB, HanAll Biopharma Co Ltd, Hanmi Pharmaceuticals Co Ltd, Hyundai Pharmaceutical Co Ltd, Immungenetics AG, Intarcia Therapeutics Inc, Ionis Pharmaceuticals Inc, Johnson & Johnson, Juno Therapeutics Inc, Kissei Pharmaceutical Co Ltd, Lead Discovery Center GmbH, Leading BioSciences Inc, Magnus Life Ltd, MedImmune LLC, Merck & Co Inc, Naia Ltd, NeuroNano Pharma Inc, NGM Biopharmaceuticals Inc, NIBEC, Nordic Bioscience A/S, Novartis AG, Novo Nordisk AS, ObeTherapy Biotechnology, Omeros Corp, OPKO Biologics Ltd, OPKO Health Inc, Oramed Pharmaceuticals Inc, Palatin Technologies Inc, Peptron Inc, Pfizer Inc, PharmaIN Corp, Poxel SA, ProMetic Life Sciences Inc, Regeneron Pharmaceuticals Inc, Renova Therapeutics Inc, Reviva Pharmaceuticals Inc, Saniona AB, Sanofi, Seres Therapeutics Inc, Shionogi & Co Ltd, Sinil Pharmaceutical Co Ltd, SJT Molecular Research SL, Takeda Pharmaceutical Co Ltd, Toray Industries Inc, Vicore Pharma AB, Viking Therapeutics Inc, Vivus Inc, WhanIn Pharmaceutical Co Ltd, XL-protein GmbH, Yuhan Corp, Yuyu Pharma Inc, Zafgen Inc, Zealand Pharma AS.

Request for a Sample Copy of this Research Report at: https://www.marketinsightsreports.com/reports/0926874981/obesity-pipeline-review-h1-2018/inquiry?source=apexnews&Mode=01

Scope:

  1. The pipeline guide provides a snapshot of the global therapeutic landscape of Obesity Pipeline.
    2. The pipeline guide reviews pipeline therapeutics for Obesity Pipeline by companies and universities/research institutes based on information derived from company and industry-specific sources.
    3. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    4. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    5. The pipeline guide reviews key companies involved in Obesity Pipeline therapeutics and enlists all their major and minor projects.
    6. The pipeline guide evaluates Obesity Pipeline therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    7. The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    8. The pipeline guide reviews latest news related to pipeline therapeutics for Obesity Pipeline

Browse full Report at: https://www.marketinsightsreports.com/reports/0926874981/obesity-pipeline-review-h1-2018?source=apexnews&Mode=01

Reasons to buy this Report:

1. procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
2. Find and recognize significant and varied types of therapeutics under development for Obesity Pipeline.
Classify potential new clients or partners in the target demographic.
3. Develop tactical initiatives by understanding the focus areas of leading companies.
4. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
5. Formulate corrective measures for pipeline projects by understanding Obesity Pipeline depth and focus of Indication therapeutics.
6. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
7. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Important Points Covered In Table of Content are:

Therapeutics Assessment, Assessment by Target, Assessment by Mechanism of Action, Assessment by Route of Administration, Assessment by Molecule Type, Pipeline Overview, Pipeline by Companies, Pipeline by Universities/Institutes, Products under Development by Companies, Products under Development by Universities/Institutes.